Granite Point Capital Management, L.P. Neurocrine Biosciences Inc Transaction History
Granite Point Capital Management, L.P.
- $0
- Q3 2023
A detailed history of Granite Point Capital Management, L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Granite Point Capital Management, L.P. holds 150,000 shares of NBIX stock, worth $18.7 Million. This represents 1.1% of its overall portfolio holdings.
Number of Shares
150,000Holding current value
$18.7 Million% of portfolio
1.1%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
649Shares Held
97.1MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.77 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.24 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$691 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$607 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$333 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...